VRCA
Verrica Pharmaceuticals Inc.$4.57-0.21 (-4.50%)Prev Close$4.78·MCap$53.9M·P/E—·Vol41.9K·Yield—
▲
Buys (12M)
9
$18.18M
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$18.18M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Verrica Pharmaceuticals Inc. (VRCA) has been exclusively buying, with 9 insider purchases totaling $18.18M and 0 insider sales totaling $0.00. The most recent insider transaction was by Kirby John J. (officer: Interim CFO), who purchased $24.6K worth of shares on Aug 18, 2026. Verrica Pharmaceuticals Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $53.9M.
VRCA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Kirby John J. | officer: Interim CFO | Buy | 5,000 | $4.93 | $24.6K | 23,962+26% |
| Aug 18, 2026 | Zawitz David | officer: Chief Operating Officer | Buy | 6,000 | $4.98 | $29.9K | 27,000+29% |
| Aug 18, 2026 | Rosenberg Noah L. | officer: CMO | Buy | 6,230 | $4.91 | $30.6K | 8,587+264% |
| Aug 18, 2026 | Rieger Jayson | director, officer: CEO and President | Buy | 25,000 | $5.03 | $125.8K | 207,593 |
| Nov 25, 2025 | Kirby John J. | Interim CFO | Buy | 3,536 | $4.24 | $15.0K | 0 |
| Nov 25, 2025 | Manning Paul B | Director | Buy | 4,126,142 | $4.24 | $17.51M38.7% OS | 0 |
| Nov 25, 2025 | Rieger Jayson | CEO and President | Buy | 94,311 | $4.24 | $400.1K0.9% OS | 0 |
| Nov 25, 2025 | Rosenberg Noah L. | CMO | Buy | 2,357 | $4.24 | $10.0K | 0 |
| Nov 25, 2025 | Zawitz David | Chief Operating Officer | Buy | 10,000 | $4.24 | $42.4K | 0 |
| Mar 14, 2025 | Hayes Christopher G. | CHIEF LEGAL OFFICER | Sell | 4,315 | $0.65 | $2.8K | 0 |
| Aug 28, 2024 | Bonaccorso Joe | CHIEF COMMERCIAL OFFICER | Sell | 33,702 | $2.61 | $87.8K | 82,107-29% |
| Aug 28, 2024 | Goldenberg Gary | Chief Medical Officer | Sell | 13,489 | $2.61 | $35.2K | 97,862 |
| Aug 28, 2024 | Hayes Christopher G. | CHIEF LEGAL OFFICER | Sell | 35,713 | $2.61 | $93.1K | 115,303 |
| Aug 28, 2024 | Kohler Terry | CHIEF FINANCIAL OFFICER | Sell | 29,719 | $2.61 | $77.5K | 52,596-36% |
| Aug 28, 2024 | White Ted | PRESIDENT AND CEO | Sell | 34,000 | $2.61 | $88.6K | 224,988 |
| Jul 23, 2024 | Bonaccorso Joe | CHIEF COMMERCIAL OFFICER | Sell | 25,576 | $7.06 | $180.6K | 106,931 |
| Jul 23, 2024 | Goldenberg Gary | Chief Medical Officer | Sell | 18,507 | $7.06 | $130.7K | 107,836 |
| Jul 23, 2024 | Hayes Christopher G. | CHIEF LEGAL OFFICER | Sell | 21,740 | $7.06 | $153.5K | 141,577 |
| Jul 23, 2024 | White Ted | PRESIDENT AND CEO | Sell | 32,623 | $7.06 | $230.3K | 250,121 |
| Dec 29, 2023 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 321,616 | $7.17 | $2.31M3.0% OS | 7,099,182 |
| Dec 26, 2023 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 504,652 | $6.45 | $3.26M4.7% OS | 6,777,566 |
| Dec 19, 2023 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 1,233,931 | $5.63 | $6.94M11.6% OS | 6,272,914 |
| Nov 16, 2023 | Bonaccorso Joe | Chief Commercial Officer | Sell | 32,846 | $2.94 | $96.7K | 103,658 |
| Nov 16, 2023 | Goldenberg Gary | Chief Medical Officer | Sell | 8,853 | $2.94 | $26.1K | 89,293 |
| Nov 16, 2023 | Hayes Christopher G. | Chief Legal Officer | Sell | 33,699 | $2.94 | $99.2K | 134,784 |
| Nov 16, 2023 | Kohler Terry | Chief Financial Officer | Sell | 28,084 | $2.94 | $82.7K | 44,048-39% |
| Nov 16, 2023 | White Ted | President and CEO | Sell | 33,699 | $2.94 | $99.2K | 181,648 |
| Jul 25, 2023 | Bonaccorso Joe | Chief Commercial Officer | Sell | 38,262 | $4.83 | $184.8K | 62,738-38% |
| Jul 25, 2023 | Goldenberg Gary | Chief Medical Officer | Sell | 28,699 | $4.83 | $138.6K | 70,110-29% |
| Jul 25, 2023 | Hayes Christopher G. | Chief Legal Officer | Sell | 33,789 | $4.83 | $163.2K | 81,925-29% |
| Jul 25, 2023 | White Ted | President and CEO | Sell | 50,677 | $4.83 | $244.8K | 128,789-28% |
| Jul 24, 2023 | Manning Paul B | Director | Buy | 200,000 | $5.02 | $1.00M1.9% OS | 7,851,128 |
| Jul 11, 2022 | Hayes Christopher G. | Chief Legal Officer | Buy | 7,500 | $3.40 | $25.5K | 15,714+91% |
| Jul 5, 2022 | Goldenberg Gary | Chief Medical Officer | Buy | 23,809 | $2.10 | $50.0K | 23,809 |
| Jul 5, 2022 | Hayes Christopher G. | Chief Legal Officer | Buy | 5,714 | $2.10 | $12.0K | 8,214+229% |
| Jul 5, 2022 | Manning Paul B | Director | Buy | 4,761,904 | $2.10 | $10.00M44.7% OS | 13,651,128+54% |
| Jul 5, 2022 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 1,428,571 | $2.10 | $3.00M13.4% OS | 5,038,983+40% |
| Jul 5, 2022 | Stalfort John A III | Director | Buy | 238,095 | $2.10 | $500.0K2.2% OS | 700,205+52% |
| Jul 5, 2022 | White Ted | President and CEO | Buy | 23,809 | $2.10 | $50.0K | 29,466+421% |
| Dec 6, 2021 | Manning Paul B | Director | Buy | 50,000 | $9.36 | $467.9K | 8,149,394 |
| Jun 7, 2021 | DAVIS A BRIAN | Chief Financial Officer | Buy | 5,000 | $9.89 | $49.5K | 12,900+63% |
| Jun 7, 2021 | Hayes Christopher G. | Chief Legal Officer | Buy | 2,500 | $9.79 | $24.5K | 2,500 |
| Jun 7, 2021 | White Ted | President and CEO | Buy | 4,000 | $9.95 | $39.8K | 21,966 |
| Mar 29, 2021 | Manning Paul B | Director | Buy | 739,830 | $14.75 | $10.91M6.9% OS | 739,830 |
VRCA Insider Buying Activity
The following table shows recent insider purchases of Verrica Pharmaceuticals Inc. (VRCA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Kirby John J. | officer: Interim CFO | Buy | 5,000 | $4.93 | $24.6K | 23,962+26% |
| Aug 18, 2026 | Zawitz David | officer: Chief Operating Officer | Buy | 6,000 | $4.98 | $29.9K | 27,000+29% |
| Aug 18, 2026 | Rosenberg Noah L. | officer: CMO | Buy | 6,230 | $4.91 | $30.6K | 8,587+264% |
| Aug 18, 2026 | Rieger Jayson | director, officer: CEO and President | Buy | 25,000 | $5.03 | $125.8K | 207,593 |
| Nov 25, 2025 | Kirby John J. | Interim CFO | Buy | 3,536 | $4.24 | $15.0K | 0 |
| Nov 25, 2025 | Manning Paul B | Director | Buy | 4,126,142 | $4.24 | $17.51M38.7% OS | 0 |
| Nov 25, 2025 | Rieger Jayson | CEO and President | Buy | 94,311 | $4.24 | $400.1K0.9% OS | 0 |
| Nov 25, 2025 | Rosenberg Noah L. | CMO | Buy | 2,357 | $4.24 | $10.0K | 0 |
| Nov 25, 2025 | Zawitz David | Chief Operating Officer | Buy | 10,000 | $4.24 | $42.4K | 0 |
| Dec 29, 2023 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 321,616 | $7.17 | $2.31M3.0% OS | 7,099,182 |
| Dec 26, 2023 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 504,652 | $6.45 | $3.26M4.7% OS | 6,777,566 |
| Dec 19, 2023 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 1,233,931 | $5.63 | $6.94M11.6% OS | 6,272,914 |
| Jul 24, 2023 | Manning Paul B | Director | Buy | 200,000 | $5.02 | $1.00M1.9% OS | 7,851,128 |
| Jul 11, 2022 | Hayes Christopher G. | Chief Legal Officer | Buy | 7,500 | $3.40 | $25.5K | 15,714+91% |
| Jul 5, 2022 | Goldenberg Gary | Chief Medical Officer | Buy | 23,809 | $2.10 | $50.0K | 23,809 |
| Jul 5, 2022 | Hayes Christopher G. | Chief Legal Officer | Buy | 5,714 | $2.10 | $12.0K | 8,214+229% |
| Jul 5, 2022 | Manning Paul B | Director | Buy | 4,761,904 | $2.10 | $10.00M44.7% OS | 13,651,128+54% |
| Jul 5, 2022 | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | 1,428,571 | $2.10 | $3.00M13.4% OS | 5,038,983+40% |
| Jul 5, 2022 | Stalfort John A III | Director | Buy | 238,095 | $2.10 | $500.0K2.2% OS | 700,205+52% |
| Jul 5, 2022 | White Ted | President and CEO | Buy | 23,809 | $2.10 | $50.0K | 29,466+421% |
| Dec 6, 2021 | Manning Paul B | Director | Buy | 50,000 | $9.36 | $467.9K | 8,149,394 |
| Jun 7, 2021 | DAVIS A BRIAN | Chief Financial Officer | Buy | 5,000 | $9.89 | $49.5K | 12,900+63% |
| Jun 7, 2021 | Hayes Christopher G. | Chief Legal Officer | Buy | 2,500 | $9.79 | $24.5K | 2,500 |
| Jun 7, 2021 | White Ted | President and CEO | Buy | 4,000 | $9.95 | $39.8K | 21,966 |
| Mar 29, 2021 | Manning Paul B | Director | Buy | 739,830 | $14.75 | $10.91M6.9% OS | 739,830 |
VRCA Insider Selling Activity
The following table shows recent insider sales of Verrica Pharmaceuticals Inc. (VRCA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 14, 2025 | Hayes Christopher G. | CHIEF LEGAL OFFICER | Sell | 4,315 | $0.65 | $2.8K | 0 |
| Aug 28, 2024 | Bonaccorso Joe | CHIEF COMMERCIAL OFFICER | Sell | 33,702 | $2.61 | $87.8K | 82,107-29% |
| Aug 28, 2024 | Goldenberg Gary | Chief Medical Officer | Sell | 13,489 | $2.61 | $35.2K | 97,862 |
| Aug 28, 2024 | Hayes Christopher G. | CHIEF LEGAL OFFICER | Sell | 35,713 | $2.61 | $93.1K | 115,303 |
| Aug 28, 2024 | Kohler Terry | CHIEF FINANCIAL OFFICER | Sell | 29,719 | $2.61 | $77.5K | 52,596-36% |
| Aug 28, 2024 | White Ted | PRESIDENT AND CEO | Sell | 34,000 | $2.61 | $88.6K | 224,988 |
| Jul 23, 2024 | Bonaccorso Joe | CHIEF COMMERCIAL OFFICER | Sell | 25,576 | $7.06 | $180.6K | 106,931 |
| Jul 23, 2024 | Goldenberg Gary | Chief Medical Officer | Sell | 18,507 | $7.06 | $130.7K | 107,836 |
| Jul 23, 2024 | Hayes Christopher G. | CHIEF LEGAL OFFICER | Sell | 21,740 | $7.06 | $153.5K | 141,577 |
| Jul 23, 2024 | White Ted | PRESIDENT AND CEO | Sell | 32,623 | $7.06 | $230.3K | 250,121 |
| Nov 16, 2023 | Bonaccorso Joe | Chief Commercial Officer | Sell | 32,846 | $2.94 | $96.7K | 103,658 |
| Nov 16, 2023 | Goldenberg Gary | Chief Medical Officer | Sell | 8,853 | $2.94 | $26.1K | 89,293 |
| Nov 16, 2023 | Hayes Christopher G. | Chief Legal Officer | Sell | 33,699 | $2.94 | $99.2K | 134,784 |
| Nov 16, 2023 | Kohler Terry | Chief Financial Officer | Sell | 28,084 | $2.94 | $82.7K | 44,048-39% |
| Nov 16, 2023 | White Ted | President and CEO | Sell | 33,699 | $2.94 | $99.2K | 181,648 |
| Jul 25, 2023 | Bonaccorso Joe | Chief Commercial Officer | Sell | 38,262 | $4.83 | $184.8K | 62,738-38% |
| Jul 25, 2023 | Goldenberg Gary | Chief Medical Officer | Sell | 28,699 | $4.83 | $138.6K | 70,110-29% |
| Jul 25, 2023 | Hayes Christopher G. | Chief Legal Officer | Sell | 33,789 | $4.83 | $163.2K | 81,925-29% |
| Jul 25, 2023 | White Ted | President and CEO | Sell | 50,677 | $4.83 | $244.8K | 128,789-28% |
VRCA Insiders
Similar Stocks to VRCA
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B